STAT Plus: When off-label may mean off-target: How would doctors and insurers navigate demand for a new, narrow Alzheimer’s drug?
ALEX HOGAN/STAT
If Biogen's aducanumab is approved, there are crucial questions on access, pricing, and coverage that will need to be sorted out.
.png)
No hay comentarios:
Publicar un comentario